CAI
Clinical Asset Index
by VOS Supply Group
Drugs · acquisition-cost intelligence

glyburide and metformin hydrochloride

· ingredient glyburideBiguanides· GLYBURIDE 1.25 mg/1; METFORMIN HYDROCHLORIDE 250 mg/1; GLYBURIDE 2.5 mg/1; METFORMIN HYDROCHLORIDE 500 mg/1; GLYBURIDE 5 mg/1; METFORMIN HYDROCHLORIDE 500 mg/1
What this is. Acquisition-cost intelligence for pharmacy & clinic buyers — the historical trend, generic-equivalent costs, and Part D posture. NADAC is a pharmacy acquisition cost (the national average pharmacies pay), not a retail or cash price — for consumer cash prices use GoodRx/your plan.
Acquisition benchmark · NADAC per EA
$0.18044
NADAC — pharmacy acquisition cost, not a retail/cash price

Acquisition-cost history

Weekly NADAC per EA — the trend nobody else shows. 6 weeks.

2025-12-172026-05-20

Same-ingredient options by acquisition cost

Other glyburide products, cheapest acquisition cost first. Per EA — confirm strength/form equivalence before switching.

ProductNADAC / EAvs this
glyburide$0.06923−$0.11120
Glyburide$0.12808−$0.05240

Medicare Part D coverage · CY2026

On 183 plan formularies · typical tier 1
Prior auth 20% · Step therapy 0% · Quantity limit 36% of formularies

Sources: CMS NADAC (pharmacy acquisition cost), FDA NDC + RxNorm (identity), RxClass (therapeutic class), CMS Medicare Part D formulary (coverage). Observed reference data for professional buyers — not a retail/cash price, not pricing or medical advice. Verify before purchasing or substituting.